The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Tuning of Antigen Sensitivity by T Cell Receptor-Dependent Negative Feedback Controls T Cell Effector Function in Inflamed Tissues
Open accessAbstract
Activated T cells must mediate effector responses sufficient to clear pathogens while avoiding excessive tissue damage. Here we have combined dynamic intravital microscopy with ex vivo assessments of T cell cytokine responses to generate a detailed spatiotemporal picture of CD4+ T cell effector regulation in the skin. In response to antigen, effector T cells arrested transiently on antigen presenting cells, briefly producing cytokine and then resuming migration. Antigen recognition led to PD-1 upregulation of the programmed death-1 (PD-1) glycoprotein by T cells and blocking its canonical ligand, programmed death-ligand 1 (PD-L1), lengthened the duration of migration arrest and cytokine production, showing that PD-1 interaction with PD-L1 is a major negative feedback regulator of antigen responsiveness. We speculate that the immune system employs a mechanism involving T cell recruitment, transient activation, and rapid desensitization, allowing the T cell response to rapidly adjust to changes in antigen presentation and minimize collateral injury to the host.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Differentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 2×
“If the antigen amount is stable or falling, however, T cells already at the site of infection will cease to participate in the response and continued effector activity will be dependent on newly arriving effector T cells coming from stem cell-like central memory cells (Gattinoni et al., 2011) and capable of being acti…”
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · cited 2×
“…its ligands on APC can limit the capacity of antigen to induce T cell migration arrest and response (Fife et al., 2009) and are further supported by the recent demonstration that PD-1 interactions can inhibit proximal TCR signaling and thus limit the TCR-induced stop signal (Yokosuka et al., 2012).”
Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions.
Bartholomäus, I., Kawakami, N., Odoardi, F., Schläger, C., Miljkovic, D., Ellwart, J. W., Klinkert, W. E. F., Flügel-Koch, C., Issekutz, T. B., Wekerle, H., et al. (2009) · Nature · doi:10.1038/nature08478 · Cited by 685 · cited 2×
“…2004; Miller et al., 2002; Stoll et al., 2002), this method has more recently been used to analyze effector T cells in various peripheral sites (Bartholomäus et al., 2009; Beattie et al., 2010; Egen et al., 2008, 2011; Fife et al., 2009; Filipe-Santos et al., 2009; Kawakami et al., 2005; Kim…”
Wolf, A. J., Desvignes, L., Linas, B., Banaiee, N., Tamura, T., Takatsu, K., & Ernst, J. D. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071367 · Cited by 580
Myelomonocytic cell recruitment causes fatal CNS vascular injury during acute viral meningitis
Kim, J. V., Kang, S. S., Dustin, M. L., & McGavern, D. B. (2009) · Nature · doi:10.1038/nature07591 · Cited by 326
Kawakami, N., Nägerl, U. V., Odoardi, F., Bonhoeffer, T., Wekerle, H., & Flügel, A. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050011 · Cited by 248 · cited 5×
“Previous studies have demonstrated that effector T cells arrest migration when they contact a high potency antigen available at adequate density on tissue APCs (Bartholomäus et al., 2009; Beattie et al., 2010; Egen et al., 2011; Fife et al., 2009; Filipe-Santos et al., 2009; Kawakami et al., 2005; Kim et al., 2009; Ma…”
InfluentialSchneider, H., Smith, X., Liu, H., Bismuth, G., & Rudd, C. E. (2008) · European Journal of Immunology · doi:10.1002/eji.200737423 · Cited by 116 · cited 2×
“Alternatively, several T cell surface molecules have been proposed to actively inhibit antigen-induced stopping and promote T cell motility, including CTLA4 (Downey et al., 2008; Schneider et al., 2006, 2008) and PD-1 (Fife et al., 2009; Schreiber et al., 2010).”
Cited by
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
Overcoming T cell exhaustion in infection and cancer
Pauken, K. E., & Wherry, E. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.008 · Cited by 1,171
Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 919
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Bengsch, B., Johnson, A. L., Kurachi, M., Odorizzi, P. M., Pauken, K. E., Attanasio, J., Stelekati, E., McLane, L. M., Paley, M. A., Delgoffe, G. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.008 · Cited by 868
“As a result, PD-1 can function asa rheostat to tuneTCRsignaling in tissuesduring infections (Honda et al., 2014;Okazaki et al., 2013).”
BackgroundThe immunological anatomy of the skin
Kabashima, K., Honda, T., Ginhoux, F., & Egawa, G. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0084-5 · Cited by 650
Self-citationThe Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Mahoney, K. M., Freeman, G. J., & McDermott, D. F. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.018 · Cited by 571
In Vivo CD4 + T Cell Differentiation and Function: Revisiting the Th1/Th2 Paradigm
Ruterbusch, M., Pruner, K. B., Shehata, L., & Pepper, M. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-103019-085803 · Cited by 550
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond
Ai, L., Xu, A., & Xu, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_3 · Cited by 526
Dustin, M. L. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0161 · Cited by 502
“destabilization in autoimmune and delayed-type hypersensitivity (93, 94), but stabilization in antiviral responses (95).”
BackgroundCXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment
Di Pilato, M., Kfuri-Rubens, R., Pruessmann, J. N., Ozga, A. J., Messemaker, M., Cadilha, B. L., Sivakumar, R., Cianciaruso, C., Warner, R. D., Marangoni, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.015 · Cited by 488
T cell migration, search strategies and mechanisms
Krummel, M. F., Bartumeus, F., & Gérard, A. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.16 · Cited by 423
Regulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 385
Insights into the initiation of TCR signaling
Chakraborty, A. K., & Weiss, A. (2014) · Nature Immunology · doi:10.1038/ni.2940 · Cited by 353
Heterogeneity of Human CD4 + T Cells Against Microbes
Sallusto, F. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112056 · Cited by 336
T Cell Dysfunction in Cancer Immunity and Immunotherapy
Xia, A., Zhang, Y., Xu, J., Yin, T., & Lu, X.-J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01719 · Cited by 341
Kurachi, M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00744-5 · Cited by 314
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 288
T follicular helper cells in space-time
Qi, H. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.94 · Cited by 277
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance
Schönrich, G., & Raftery, M. J. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00207 · Cited by 275
PD‐1 suppresses TCR‐CD8 cooperativity during T‐cell antigen recognition
Li, K., Yuan, Z., Lyu, J., Ahn, E., Davis, S. J., Ahmed, R., & Zhu, C. (2021) · Nature Communications · doi:10.1038/s41467-021-22965-9 · Cited by 81
The emerging role of ECM crosslinking in T cell mobility as a hallmark of immunosenescence in humans
Moreau, J.-F., Pradeu, T., Grignolio, A., Nardini, C., Castiglione, F., Tieri, P., Capri, M., Salvioli, S., Taupin, J.-L., Garagnani, P., et al. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.11.005 · Cited by 67
Abaza, A., Sid Idris, F., Anis Shaikh, H., Vahora, I., Moparthi, K. P., Al Rushaidi, M. T., Muddam, M. R., Obajeun, O. A., Jaramillo, A. P., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.44582 · Cited by 59
Metadata
- Authors
- Honda, T., Egen, J. G., Lämmermann, T., Kastenmüller, W., Torabi-Parizi, P., & Germain, R. N.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 40
- Issue
- 2
- Pages
- 235-247
- ISSN
- 1074-7613 (ISSN-L)
- OpenAlex
- W2036958461
- Cited by
- 237
- References
- 8
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.